Answer
Ambirix protects non-immune children and adolescents aged 1–15 years inclusive against hepatitis A and B; hepatitis B protection may await the second dose, so use is restricted to relatively low hepatitis B risk during vaccination, preferably where completion of both doses is assured.
Sources for this answer
- Ambirix suspension for injection in pre-filled syringeGlaxoSmithKline UK · emc · SmPC §4.1 Therapeutic Indications · Version 18Document updated
Sources checked